Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005003 | 0.84 | AKT1 (0.48) | CYP2D6CYP2C9EPHX2DRD2HTR2A | |
| SCHEMBL13770573 | 0.83 | CYP2D6 (0.41) | CYP2D6CYP2C9EPHX2DRD2SIGMAR1 | |
| SCHEMBL13698990 | 0.83 | HTR2A (0.43) | CYP2D6DRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL13910962 | 0.82 | CYP2D6 (0.41) | CYP2D6CYP2C9EPHX2DRD2SIGMAR1 | |
| SCHEMBL14945598 | 0.81 | HTR2A (0.42) | CYP2D6DRD2SIGMAR1HTR2AHTR2C | |
| SCHEMBL4220742 | 0.79 | HTR2C (0.49) | CYP2D6CYP2C9EPHX2DRD2SIGMAR1 | |
| SCHEMBL4222966 | 0.79 | SIGMAR1 (0.74) | CYP2D6CYP2C9EPHX2DRD2SIGMAR1 | |
| SCHEMBL13005005 | 0.79 | HTR2A (0.63) | CYP2D6DRD2HTR2AHTR2CKCNH2 | |
| Hydrochloric Acid SCHEMBL4221293 | 0.78 | HTR2C (0.48) | CYP2D6CYP2C9EPHX2DRD2SIGMAR1 | |
| SCHEMBL31430374 | 0.78 | DRD2 (0.44) | DRD2HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877745-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123241-A1 | NOVEL CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | CCR2, CXCR2, CYSLTR2 | CYP2D6 493/4885CYP2C9 573/4885EPHX2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.